AVDL Stock Overview
Operates as a biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Avadel Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.50 |
| 52 Week High | US$19.09 |
| 52 Week Low | US$9.41 |
| Beta | 0 |
| 1 Month Change | -5.06% |
| 3 Month Change | -20.21% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.24% |
Recent News & Updates
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
Dec 01
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Recent updates
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
Dec 01Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
Oct 16Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Shareholder Returns
| AVDL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.6% | -1.9% | -1.1% |
| 1Y | n/a | 6.5% | 22.4% |
Return vs Industry: Insufficient data to determine how AVDL performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AVDL performed against the US Market.
Price Volatility
| AVDL volatility | |
|---|---|
| AVDL Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVDL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVDL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 154 | Greg Divis | www.avadel.com |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc Fundamentals Summary
| AVDL fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$72.57m |
| Revenue (TTM) | US$138.16m |
7.3x
P/S Ratio-13.9x
P/E RatioIs AVDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVDL income statement (TTM) | |
|---|---|
| Revenue | US$138.16m |
| Cost of Revenue | US$11.16m |
| Gross Profit | US$127.00m |
| Other Expenses | US$199.58m |
| Earnings | -US$72.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 91.92% |
| Net Profit Margin | -52.53% |
| Debt/Equity Ratio | 48.6% |
How did AVDL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 04:31 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avadel Pharmaceuticals plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Oren Livnat | H.C. Wainwright & Co. |